MedWatch

Orifarm accuses Merck of shady tactics

Danish parallel importer, Orifarm, believes that Merck is using legal action as a way of putting pressure on the industry. Merck, who is set to face off against the Danish company in the courtroom in September, turns their guns at Orifarm instead.

Foto: Colourbox

The Danish Maritime and Commercial Court will initiate a case next month that pharmaceutical group, Merck, has raised against the biggest parallel importer in Scandinavia, Denmark-based Orifarm. It is but the latest in a number of legal cases the US company has launched against Orifarm over the years, which makes the CEO of the Danish company question the motives behind the trials.

“Merck is probably one of the most aggressive companies in the pharmaceutical world. It’s obvious to me that they have chosen a strategy of shooting at anything that moves,” Orifarm CEO, Hans Bøgh-Sørensen, tells Medwatch.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Her er de vigtigste nyheder fra MedWatch i uge 39

Et konsortium står til at overtage Ferrosan Medical Devices, der kan være klar til en børsnotering inden for en femårig tidshorisont. Derudover fortsætter kampen om medarbejderne i branchen, mens Novo Nordisk har indgået en ny aftale. Gik du glip af noget?

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier